Weight Loss
Weight Loss – Tirzepatide (Mounjaro)
In late 2022 the FDA approved a drug, Mounjaro, to treat type 2 diabetes. This drug has also shown remarkable weight-loss effects that reduced weight by 22% for participants in a clinical trial on a 15 mg dose of Tirzepatide. On October 6, 2022, the FDA granted Tirzepatide a fast-track review to be designated as a treatment for obesity. The trial will be completed in 2023, but this FDA designation gives Tirzepatide a positive way to fill a serious medical need for those with rising rates of childhood and adult obesity. Tirzepatide activates the GLP-1 and GIP receptors in the body. These receptors trigger the release of insulin from your pancreas and block glucagon, a hormone that increases blood sugar levels. As a result, Tirzepatide affects certain chemicals in your brain, decreasing food intake, increasing energy expenditures, and preventing ectopic fat deposition. These are the keys to reducing weight. Tirzepatide is injected subcutaneously once a week with or without meals. To help you lose weight, your provider will begin with a low dose of Tirzepatide and gradually increase your dose. Maintain a good diet and exercise program in addition to your Tirzepatide injections.
Book a Weight loss Consultation to see which option would be best for you!
Weight Loss – Tirzepatide
Book a Weight loss Consultation to see which option would be best for you!
Semaglutide
The FDA has approved Semaglutide for the treatment of weight loss in adults. Patients who receive injections of Semaglutide for weight management feel full longer and are less hungry. This makes it easier for most people to control their cravings and overeating urges.
Semaglutide is a GLP-1 analog, which is similar to glucagon-like peptides (GLPs). The small intestine produces GLP-1. Insulin stimulates the release of blood sugar and inhibits the release of glucagon. Weekly injections of Semaglutide help to improve glycemic control and reduce appetite and food cravings.
According to doctors, this peptide is two times more effective than prescription weight loss products available today. The average weight loss for obese or overweight adults taking Semaglutide weekly was 14.9%. More than 32% of participants lost 20% or more of their initial weight while taking Semaglutide.
Book a Weight loss Consultation to see which option would be best for you!
FAQs
What is Tirzepatide?
Tirzepatide is a dual glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptor. It is a drug proposed to help treat obesity, type 2 diabetes, and non-alcoholic fatty liver disease.
How is it administered?
Tirzepatide is administered into the subcutaneous tissue by injections.
How does it work?
Tirzepatide triggers the release of insulin that blocks glucagon or the hormone that increases blood sugar levels. It also affects chemicals in the brain, which help to decrease food intake and increase energy.
Are there any other benefits to Tirzepatide?
The effect of Tirzepatide on blood sugar levels also helps contribute to a healthy heart and improves liver health by reducing liver fat.
Are there side effects with Tirzepatide?
Side effects may include diarrhea, nausea, vomiting, and constipation. Discuss side effect possibilities with your healthcare provider.